Register
Adjuvant pembrolizumab therapy reduces recurrence risk in stage III melanoma |
Journal Updates
eMediNexus Coverage from: 
Adjuvant pembrolizumab therapy reduces recurrence risk in stage III melanoma
eMediNexus,  16 April 2018
remove_red_eye 666 Views
#Dermatology #Hematology #Oncology #Pathology and Lab Medicine #Pharmacist

0 Read Comments                

Adjuvant therapy with pembrolizumab (Keytruda) 200 mg every 3 weeks for up to 1 year in patients with high-risk stage III melanoma reduced the risk of recurrence or death by 43% with no new toxic effects identified, as per results from the phase III EORTC 1325-MG/KEYNOTE-054 trial published April 15, 2018 in the New England Journal of Medicine.
To continue reading this article
Or

Continue reading your article with a Emedinexus account..
Free Membership!